Digest Network Come funziona
Network
/
Società
Ph
Non verificato

PharmaEssentia Corporation

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

9 comunicati stampa

Guarda tutti i comunicati
07/01/2025
Industria
Scienza
Biotecnologia
Farmaceutica
Attrezzature medico-sanitarie
Oncologia
Salute
Medicina - Varie
CORRECTING and REPLACING PharmaEssentia Announces Positive Topline Phase 3 Data from SURPASS-ET Study Evaluating Ropeginterferon Alfa-2b-njft (P1101) for Essential Thrombocythemia
Fonte
PharmaEssentia Corporation
Emittente
Business Wire
1.00
0
06/01/2025
Industria
Scienza
Biotecnologia
Farmaceutica
Attrezzature medico-sanitarie
Oncologia
Salute
Medicina - Varie
PharmaEssentia Announces Positive Topline Phase 3 Data from SURPASS-ET Study Evaluating Ropeginterferon Alfa-2b-njft (P1101) for Essential Thrombocythemia
Fonte
PharmaEssentia Corporation
Emittente
Business Wire
1.00
0
19/12/2024
Web e Social Network
Fiere
Eventi
Oncologia
Salute
Sanità
Scienza
Farmaceutica
Biotecnologia
PharmaEssentia to Present at the Annual J.P. Morgan Healthcare Conference on January 16, 2025
Fonte
PharmaEssentia Corporation
Emittente
Business Wire
1.00
0
05/12/2024
Mercato del lavoro
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
PharmaEssentia Appoints Joseph R. Horvat as Global Chief Commercial Officer
Fonte
PharmaEssentia Corporation
Emittente
Business Wire
1.00
0
25/11/2024
Oncologia
Salute
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Eventi
Fiere
PharmaEssentia Announces Nine Data Presentations at ASH Annual Meeting
Fonte
PharmaEssentia Corporation
Emittente
Business Wire
1.00
0
04/09/2024
Mercato del lavoro
Industria
Biotecnologia
Sanità
Salute
Medicina - Varie
Oncologia
PharmaEssentia Announces Licensing Agreement with FORUS Therapeutics to Commercialize BESREMi® (ropeginterferon alfa-2b-njft) in Canada
Fonte
PharmaEssentia Corporation
Emittente
Business Wire
1.00
0
22/07/2024
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Mercato del lavoro
PharmaEssentia Appoints Beth A. Krewson as Head of Legal
Fonte
PharmaEssentia Corporation
Emittente
Business Wire
1.00
0
08/07/2024
Mercato del lavoro
Oncologia
Salute
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
PharmaEssentia Promotes Robert B. Geller, M.D. to General Manager
Fonte
PharmaEssentia Corporation
Emittente
Business Wire
1.00
0
25/06/2024
Industria
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
PharmaEssentia Completes Patient Enrollment for Phase 2b EXCEED-ET Trial in Essential Thrombocythemia and Phase 3b ECLIPSE-PV Trial in Polycythemia Vera
Fonte
PharmaEssentia Corporation
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0